K‑ras gene mutation as a predictor of cancer cell responsiveness to metformin

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Metformin is a widely used antidiabetic drug.
• Emerging research suggests metformin possesses anticancer properties.
• The precise mechanism of metformin's anticancer action remains unclear.

Purpose of the Study:

• To investigate the efficacy of metformin against tumors with K-ras mutations.
• To elucidate the mechanism underlying metformin's antitumor effects.
• To evaluate metformin's potential as a K-ras-targeting cancer therapeutic.

Main Methods:

• In vivo studies assessing metformin's effect on K-ras mutant and wild-type tumor growth.
• In vitro experiments measuring metformin-induced apoptosis and proliferation inhibition in various cancer cell lines.
• Analysis of cell cycle arrest and downstream effectors of the Ras signaling pathway.

Main Results:

• Metformin significantly inhibited the growth of K-ras mutant tumors in vivo, but not wild-type tumors.
• Metformin induced apoptosis and inhibited proliferation in K-ras mutant tumor cells both in vitro and in vivo.
• Metformin arrested K-ras mutant and wild-type tumor cells in the G1 phase and downregulated key Ras pathway effectors in K-ras mutant tumors.

Conclusions:

• Tumors with K-ras mutations are sensitive to metformin therapy.
• Metformin demonstrates potential as a K-ras-targeting agent for cancer treatment.
• Further research into metformin's anticancer mechanisms is warranted.